hESC-RPE
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stargardt's Macular Dystrophy
Conditions
Stargardt's Macular Dystrophy
Trial Timeline
Jan 16, 2013 → Oct 2, 2019
NCT ID
NCT02941991About hESC-RPE
hESC-RPE is a pre-clinical stage product being developed by Astellas Pharma for Stargardt's Macular Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02941991. Target conditions include Stargardt's Macular Dystrophy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02941991 | Pre-clinical | Completed |
Competing Products
6 competing products in Stargardt's Macular Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| avacincaptad pegol + Sham | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Phase 1/2 | 41 |
| SAR422459 | Sanofi | Phase 1/2 | 40 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Sanofi | Phase 2 | 51 |